GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

Indication expands to include treatment-naïve patients - - The 2021 conditional approval in previously treated patients converted to ful ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Pirtobrutinib (brand name Jaypirca) could reduce progression or death risk by 46% in patients with chronic lymphocytic ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...

结直肠癌（CRC）是全球发病率和死亡率较高的恶性肿瘤之一。随着基因组学的发展，越来越多的分子标志物被发现与结直肠癌的发生和发展密切相关。其中，神经生长因子受体酪氨酸激酶（NTRK）基因融合作为一种新兴的生物标志物，逐渐引起了研究者的关注。NTRK ...

Alzheimer’s disease is one of the world’s biggest health problems. Yet, despite the fact millions of people globally are ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...